1. Home
  2. IMAX vs SRPT Comparison

IMAX vs SRPT Comparison

Compare IMAX & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMAX
  • SRPT
  • Stock Information
  • Founded
  • IMAX 1967
  • SRPT 1980
  • Country
  • IMAX Canada
  • SRPT United States
  • Employees
  • IMAX N/A
  • SRPT N/A
  • Industry
  • IMAX
  • SRPT Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMAX
  • SRPT Health Care
  • Exchange
  • IMAX Nasdaq
  • SRPT Nasdaq
  • Market Cap
  • IMAX N/A
  • SRPT N/A
  • IPO Year
  • IMAX 1994
  • SRPT 1997
  • Fundamental
  • Price
  • IMAX $27.31
  • SRPT $17.67
  • Analyst Decision
  • IMAX Strong Buy
  • SRPT Buy
  • Analyst Count
  • IMAX 11
  • SRPT 25
  • Target Price
  • IMAX $30.36
  • SRPT $64.00
  • AVG Volume (30 Days)
  • IMAX 831.7K
  • SRPT 7.7M
  • Earning Date
  • IMAX 07-24-2025
  • SRPT 08-06-2025
  • Dividend Yield
  • IMAX N/A
  • SRPT N/A
  • EPS Growth
  • IMAX N/A
  • SRPT N/A
  • EPS
  • IMAX 0.46
  • SRPT N/A
  • Revenue
  • IMAX $359,752,000.00
  • SRPT $2,233,371,000.00
  • Revenue This Year
  • IMAX $17.23
  • SRPT $26.87
  • Revenue Next Year
  • IMAX $5.25
  • SRPT $3.15
  • P/E Ratio
  • IMAX $60.44
  • SRPT N/A
  • Revenue Growth
  • IMAX N/A
  • SRPT 59.15
  • 52 Week Low
  • IMAX $16.33
  • SRPT $16.88
  • 52 Week High
  • IMAX $29.66
  • SRPT $162.95
  • Technical
  • Relative Strength Index (RSI)
  • IMAX 47.53
  • SRPT 18.77
  • Support Level
  • IMAX $27.00
  • SRPT $18.30
  • Resistance Level
  • IMAX $28.11
  • SRPT $22.98
  • Average True Range (ATR)
  • IMAX 0.85
  • SRPT 1.43
  • MACD
  • IMAX -0.20
  • SRPT -0.49
  • Stochastic Oscillator
  • IMAX 20.34
  • SRPT 0.99

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Share on Social Networks: